Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003240 | 1.00 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL5250892 | 1.00 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL132894 | 0.94 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1TP53BP1SRD5A2 | |
| SCHEMBL863778 | 0.91 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL11008209 | 0.87 | MAPK1 (0.43) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL11003669 | 0.85 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1OPRM1OPRL1 | |
| SCHEMBL863645 | 0.85 | MAPK1 (0.42) | MAPK1L3MBTL3L3MBTL1TP53BP1OPRM1 | |
| SCHEMBL8149056 | 0.85 | MAPK1 (0.33) | MAPK1KDM4EALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1822607 | 0.84 | MAPK1 (0.45) | MAPK1ALDH1A1L3MBTL3L3MBTL1CTDSP1 | |
| SCHEMBL30761740 | 0.83 | MAPK1 (0.41) | MAPK1ALDH1A1L3MBTL3L3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-107231802-B | Heterocyclic derivatives and use thereof | 株式会社C&C新药研究所 | 2021-02-12 | — | — | CN | disclosed |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| CN-107027306-B | 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| WO-2000004019-A1 | 5-BICYCLOINDOLE COMPOUNDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000000487-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000490-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999065906-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-4485109-A | 4-Aryl-4-piperidinecarbinols | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-11-27 | — | — | US | disclosed |
| EP-0094018-A2 | 4-Aryl-4-piperidinecarbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-11-16 | — | — | EP | disclosed |
| US-4213983-A | Treating gastro-intestinal disorders and emesis with n-(heterocyclic substituted) benzamides | BEECHAM GROUP LIMITED (GB) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | MAPK1 2448/4885KDM4E 2994/4885ALDH1A1 1538/4885 |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | MAPK1 406/4885KDM4E 2813/4885ALDH1A1 4361/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | MAPK1 2448/4885KDM4E 2994/4885ALDH1A1 1538/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | MAPK1 640/4885KDM4E 3065/4885ALDH1A1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.